Beryl Drugs Limited (BOM:524606)
22.11
+0.23 (1.05%)
At close: Feb 12, 2026
Beryl Drugs Revenue
Beryl Drugs had revenue of 37.77M INR in the quarter ending December 31, 2025, a decrease of -28.86%. This brings the company's revenue in the last twelve months to 176.65M, down -12.33% year-over-year. In the fiscal year ending March 31, 2025, Beryl Drugs had annual revenue of 211.46M, down -20.89%.
Revenue (ttm)
176.65M
Revenue Growth
-12.33%
P/S Ratio
0.63
Revenue / Employee
n/a
Employees
n/a
Market Cap
111.32M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 211.46M | -55.83M | -20.89% |
| Mar 31, 2024 | 267.30M | -1.41M | -0.53% |
| Mar 31, 2023 | 268.71M | 122.67M | 84.00% |
| Mar 31, 2022 | 146.04M | 5.11M | 3.62% |
| Mar 31, 2021 | 140.93M | 12.78M | 9.97% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vivanza Biosciences | 663.49M |
| Cian Healthcare | 232.80M |
| Decipher Labs | 176.11M |
| Unjha Formulations | 148.12M |
| Norris Medicines | 72.84M |
| Hamps Bio | 71.20M |
| Colinz Laboratories | 58.40M |
| Emmessar Biotech & Nutrition | 20.06M |